27 January 2009 in Proceedings of the National Academy of Sciences
Cerebral amyloid angiopathy (CAA), the deposition of β-amyloid (Aβ) peptides in leptomeningeal and cortical blood vessels, affects the majority of patients with Alzheimer's disease (AD). Evidence suggests that vascular amyloid deposits may result from impaired clearance of neuronal Aβ along perivascular spaces. We investigated the role of perivascular macrophages in regulating CAA severity in the TgCRND8 mouse model of AD. Depletion of perivascular macrophages significantly increased the number of thioflavin S-positive cortical blood vessels. ELISA confirmed that this increase was underscored by elevations in total vascular Aβ 42 levels. Conversely, stimulation of perivascular macrophage turnover reduced cerebral CAA load, an effect that was not mediated through clearance by microglia or astrocytes. These results highlight a function for the physiological role of perivascular macrophages in the regulation of CAA and suggest that selective targeting of perivascular macrophage activation might constitute a therapeutic strategy to clear vascular amyloid.
11 June 2006 in Nature Medicine
15 October 2002 in Nature Medicine
1 June 2000 in Journal of Biological Chemistry
Inositol has 8 stereoisomers, four of which are physiologically active. myo-Inositol is the most abundant isomer in the brain and more recently shown that epi- andscyllo-inositol are also present. myo-Inositol complexes with Aβ42 in vitro to form a small stable micelle. The ability of inositol stereoisomers to interact with and stabilize small Aβ complexes was addressed. Circular dichroism spectroscopy demonstrated that epi- and scyllo- but not chiro-inositol were able to induce a structural transition from random to β-structure in Aβ42. Alternatively, none of the stereoisomers were able to induce a structural transition in Aβ40. Electron microscopy demonstrated that inositol stabilizes small aggregates of Aβ42. We demonstrate that inositol-Aβ interactions result in a complex that is non-toxic to nerve growth factor-differentiated PC-12 cells and primary human neuronal cultures. The attenuation of toxicity is the result of Aβ-inositol interaction, as inositol uptake inhibitors had no effect on neuronal survival. The use of inositol stereoisomers allowed us to elucidate an important structure-activity relationship between Aβ and inositol. Inositol stereoisomers are naturally occurring molecules that readily cross the blood-brain barrier and may represent a viable treatment for AD through the complexation of Aβ and attenuation of Aβ neurotoxic effects.
15 December 1999 in European Journal of Biochemistry
Proteoglycans and their constituent glycosaminoglycans are associated with all amyloid deposits and may be involved in the amyloidogenic pathway. In Alzheimer’s disease, plaques are composed of the amyloid‐β peptide and are associated with at least four different proteoglycans. Using CD spectroscopy, fluorescence spectroscopy and electron microscopy, we examined glycosaminoglycan interaction with the amyloid‐β peptides 1–40 (Aβ40) and 1–42 (Aβ42) to determine the effects on peptide conformation and fibril formation. Monomeric amyloid‐β peptides in trifluoroethanol, when diluted in aqueous buffer, undergo a slow random to amyloidogenic β sheet transition. In the presence of heparin, heparan sulfate, keratan sulfate or chondroitin sulfates, this transition was accelerated with Aβ42 rapidly adopting a β‐sheet conformation. This was accompanied by the appearance of well‐defined amyloid fibrils indicating an enhanced nucleation of Aβ42. Incubation of preformed Aβ42 fibrils with glycosaminoglycans resulted in extensive lateral aggregation and precipitation of the fibrils. The glycosaminoglycans differed in their relative activities with the chondroitin sulfates producing the most pronounced effects. The less amyloidogenic Aβ40 isoform did not show an immediate structural transition that was dependent upon the shielding effect by the phosphate counter ion. Removal or substitution of phosphate resulted in similar glycosaminoglycan‐induced conformational and aggregation changes. These findings clearly demonstrate that glycosaminoglycans act at the earliest stage of fibril formation, namely amyloid‐β nucleation, and are not simply involved in the lateral aggregation of preformed fibrils or nonspecific adhesion to plaques. The identification of a structure–activity relationship between amyloid‐β and the different glycosaminoglycans, as well as the condition dependence for glycosaminoglycan binding, are important for the successful development and evaluation of glycosaminoglycan‐specific therapeutic interventions.
1 November 2017 in Ageing Research Reviews